FDA — authorised 2 December 2005
- Application: BLA021859
- Marketing authorisation holder: HALOZYME THERAP
- Status: supplemented
FDA authorised Hylenex on 2 December 2005 · 160 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 2 December 2005; FDA has authorised it.
HALOZYME THERAP holds the US marketing authorisation.